Method for treating a mental disorder

• US 20020013270A1
• Filed: 05/25/2001
• Published: 01/31/2002
• Est. Priority Date: 06/05/2000
• Status: Abandoned Application

• Current Assignee: Ellen R. Bolte
• Original Assignee: Ellen R. Bolte
• Inventors: Bolte, Ellen R.
• Application Number:
  US09/866,033
• Publication Number:
  US 20020013270A1
• Time in Patent Office: Days
• US Class Current: 514/8
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/397 having four-membered rings, e.g. azetidine
• CPC Class Codes: A61K 31/545 Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins, cefaclor, or cephalexine
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/742 Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• CPC Class Codes: A61K 35/744 Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 35/76 Viruses; Subviral particles; Bacteriophages
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A method of treating an individual exhibiting at least one symptom of a mental disorder is provided which comprises administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder. This invention also pertains to a method of treating an individual exhibiting at least one symptom of a mental disorder by administering a probiotic mixture to replenish gastrointestinal microbes.

RELATED APPLICATIONS

This application claims the benefits of United States Provisional Application No. 60/209,712 entitled “Method For Treating Autism” filed on Jun. 5, 2000, United States Provisional Application No. 60/214,813 entitled “Therapies for Gastrointestinal and Neurological Disorders” filed on Jun. 28, 2000, and United States Provisional Application No. 60/240,582 entitled “Method For Treating Autism—Addition 1” filed on Oct. 16, 2000 which are incorporated herein by reference and made a part hereof.

Claims

1. A method of treating an individual exhibiting at least one symptom of a mental disorder, the method comprising administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder.

2. The method of claim 1 wherein the mental disorder is selected from the group consisting of anxiety disorder, attention deficit/hyperactivity disorder, autistic disorder, bipolar disorder, major depression, mood disorder, pervasive developmental disorder, psychotic disorder and schizophrenia.

3. The method of claim 1 wherein the antimicrobial composition is selected from the group consisting of cationic peptides, cephalosporins, glycopeptides, macrolides, nitroimidazoles, polypeptides, semi-synthetic penicillins, and polymyxins.

4. The method of claim 3 wherein the antimicrobial composition is further selected from the group consisting of amoxicillin, bacitracin, cefpodoxime proxetil, clarithromycin, metronidazole, polymyxin B, and vancomycin.

5. The method of claim 1 wherein the antimicrobial agent can be administered orally.

6. The method of claim 1 wherein the antimicrobial agent can be administered rectally.

7. The method of claim 1 wherein the antimicrobial agent can be administered parenterally.

8. A kit for treating an individual exhibiting at least one symptom of a mental disorder, the kit comprising an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder.

9. The kit of claim 8 wherein the mental disorder is selected from the group consisting of anxiety disorder, attention deficit/hyperactivity disorder, autistic disorder, bipolar disorder, major depression, mood disorder, pervasive developmental disorder, psychotic disorder and schizophrenia.

10. The kit of claim 8 wherein the antimicrobial composition is selected from the group consisting of cationic peptides, cephalosporins, glycopeptides, macrolides, nitroimidazoles, polypeptides, semi-synthetic penicillins, and polymyxins.

11. The kit of claim 10 wherein the antimicrobial composition is further selected from the group consisting of amoxicillin, bacitracin, cefpodoxime proxetil, clarithromycin, metronidazole, polymyxin B, and vancomycin.

12. The kit of claim 8 wherein the antimicrobial agent can be administered orally.

13. The kit of claim 8 wherein the antimicrobial agent can be administered rectally.

14. The kit of claim 8 wherein the antimicrobial agent can be administered parenterally.

15. A method of treating an individual exhibiting at least one symptom of a mental disorder, the method comprising administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder and administering to the individual a probiotic mixture to replenish gastrointestinal microbes.

16. The method of claim 15 wherein the mental disorder is selected from the group consisting of anxiety disorder, attention deficit/hyperactivity disorder, autistic disorder, bipolar disorder, major depression, mood disorder, pervasive developmental disorder, psychotic disorder and schizophrenia.

17. The method of claim 15 wherein the antimicrobial composition is selected from the group consisting of cationic peptides, cephalosporins, glycopeptides, macrolides, nitroimidazoles, polypeptides, semi-synthetic penicillins, and polymyxins.

18. The method of claim 17 wherein the antimicrobial composition is further selected from the group consisting of amoxicillin, bacitracin, cefpodoxime proxetil, clarithromycin, metronidazole, polymyxin B, and vancomycin.

19. The method of claim 15 wherein the probiotic mixture comprises at least one gastrointestinal microbe.

20. The method of claim 19 wherein the at least one gastrointestinal microbe is selected from the group consisting of Bifidobactrium adolescentis, Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides vulgatus, Clostridium bifermentans, Clostridium innocuum, Clostridium ramosum, Escherichia coli, Eubacterium aerofaciens, Peptostreptococcus productus, and Streptococcus faecalis.

21. The method of claim 15 wherein the antimicrobial agent can be administered orally.

22. The method of claim 15 wherein the antimicrobial agent can be administered rectally.

23. The method of claim 15 wherein the antimicrobial agent can be administered parenterally.

24. The method of claim 15 wherein the probiotic mixture can be administered orally.

25. The method of claim 15 wherein the probiotic mixture can be administered rectally.

26. A kit for treating an individual exhibiting at least one symptom of a mental disorder, the method comprising administering to the individual an antimicrobial composition in an amount effective to inhibit or eliminate the at least one symptom of the disorder and administering to the individual a probiotic mixture to replenish gastrointestinal microbes.

27. The kit according to claim 26 wherein the mental disorder is selected from the group consisting of anxiety disorder, attention deficit/hyperactivity disorder, autistic disorder, bipolar disorder, major depression, mood disorder, pervasive developmental disorder, psychotic disorder and schizophrenia.

28. The kit according to claim 26 wherein the antimicrobial composition is selected from the group consisting of cationic peptides, cephalosporins, glycopeptides, macrolides, nitroimidazoles, polypeptides, semi-synthetic penicillins, and polymyxins.

29. The kit according to claim 28 wherein the antimicrobial composition is further selected from the group consisting of amoxicillin, bacitracin, cefpodoxime proxetil, clarithromycin, metronidazole, polymyxin B, and vancomycin.

30. The kit according to claim 26 wherein the probiotic mixture comprises at least one gastrointestinal microbe.

31. The kit according to claim 30 wherein the at least one gastrointestinal microbe is selected from the group consisting of Bifidobactrium adolescentis, Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotamicron, Bacteroides vulgatus, Clostridium bifermentans, Clostridium innocuum, Clostridium ramosum, Escherichia coli, Eubacterium aerofaciens, Peptostreptococcus productus, and Streptococcus faecalis.

32. The kit according to claim 26 wherein the antimicrobial agent can be administered orally.

33. The kit according to claim 26 wherein the antimicrobial agent can be administered rectally.

34. The kit according to claim 26 wherein the antimicrobial agent can be administered parenterally.

35. The kit according to claim 26 wherein the probiotic mixture can be administered orally.

36. The kit according to claim 26 wherein the probiotic mixture can be administered rectally.